Aurinia Pharmaceuticals Inc. (AUPH) Form 10-Q — Oct 30, 2026
Aurinia Pharmaceuticals posted Q3 2026 revenue of $83.7 million, up 14% year over year, with LUPKYNIS net product sales of $79.4 million up 12% on continued lupus nephritis market penetration. Nine-month net income reached $103.5 million versus $76.4 million a year ago, with diluted EPS of $0.76 versus $0.55. The balance sheet strengthened: cash, cash equivalents, restricted cash and investments rose to $486.9 million from $398.0 million at year-end 2025, and operating cash flow grew 46% to $131.5 million for the nine months. The company continues buying back stock, repurchasing $74.9 million of shares in the period and $213.4 million cumulatively.
Key figures
- Eps
- 0.78
- Revenue
- 244624000
- Net Income
- 103472000
- Revenue Yoy
- 18.8% (nine months: $244.6M vs $205.9M)
- Cash Position
- 486880000
- Shares Outstanding
- 133998660
- Buybacks 9m
- $74.9M (5.0M shares)
- Total assets
- 825704000
- Q3 net income
- 31703000
- Q3 diluted eps
- 0.23
- Q3 revenue yoy
- +13.9% ($83.7M vs $73.5M)
- Gross margin q3
- 90%
- Q3 total revenue
- 83699000
- Q3 net product sales
- 79418000
- Effective tax rate 9m
- 21.3%
- Income tax expense 9m
- 27954000
- Q3 lupkynis sales yoy
- +12% ($79.4M vs $70.6M)
- Operating cash flow 9m
- 131493000
- Total buybacks to date
- $213.4M (23.3M shares)
- Operating cash flow yoy
- +46% ($131.5M vs $90.0M)
- Kezar acquisition consideration
- 55488000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.